Cab-Axl-Adc
Undifferentiated Pleomorphic Sarcoma
Explore 5 assets in Undifferentiated Pleomorphic Sarcoma →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
BioAtla, Inc.
Modality
antibody_drug_conjugate
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03425279CT.gov CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Undifferentiated Pleomorphic Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cab-Axl-Adc (this asset) | BioAtla, Inc. | P1/2 | CCC · 50 |
| Sorafenib | National Cancer Institute (NCI) | P2 | B |
| Vismodegib | National Cancer Institute (NCI) | P1/2 | CCC |
| Ipilimumab | Xencor, Inc. | P1 | CC |
| Samrotamab Vedotin | AbbVie | P1 | CC |
| Izuralimab | Xencor, Inc. | P1 | CC |
| Futibatinib | Boundless Bio, Inc. | P1 | CC |
| Bbi-355 | Boundless Bio, Inc. | P1 | CC |
| okn4395 | Epkin | P1 | CC |
+4 more in the Undifferentiated Pleomorphic Sarcoma cohort
Other indications for Cab-Axl-Adc
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | B · 57 |
| Myxofibrosarcoma | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cab-Axl-Adc in Undifferentiated Pleomorphic Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cab-axl-adc-undifferentiated-pleomorphic-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →